Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Unoeste Universidade do Oeste Paulista, Presidente Prudente, São Paulo, Brazil.
Oncologist. 2020 Feb;25(2):170-182. doi: 10.1634/theoncologist.2019-0600. Epub 2019 Nov 12.
The loss of muscle mass, known as sarcopenia, is a natural process of aging that is associated with adverse health outcomes regardless of age. Because cancer is a disease of aging, interest in sarcopenia and its potential impact in multiple cancer populations has increased significantly. Bioelectrical impedance analysis (BIA) is a guideline-accepted method for sarcopenia detection. This systematic review assesses the literature pertaining to BIA use in the detection of sarcopenia in adults with cancer.
In this systematic review, a search of the literature for randomized controlled trials and observational studies was conducted using MEDLINE, Cochrane CENTRAL, and EMBASE, through July 15, 2019. The study is registered at Prospero (CRD 42019130707). For study inclusion, patients had to be aged 18 years or older and diagnosed with solid or hematological neoplasia, and BIA had to be used to detect sarcopenia.
Through our search strategy, 5,045 articles were identified, of which 24 studies were selected for inclusion in the review (total number of 3,607 patients). In five studies, BIA was rated comparable to axial computed tomography (CT) scan, calf circumference, or grip strength for sarcopenia screening. In 14 studies, BIA-identified sarcopenia was associated with adverse clinical outcomes.
BIA is an accurate method for detecting sarcopenia in adults with cancer prior to treatment and is a viable alternative to CT, dual-energy x-ray absorptiometry, and magnetic resonance imaging in oncology clinical practice.
Bioelectrical impedance analysis (BIA) is an attractive method for identifying sarcopenic patients in clinical practice because it provides an affordable, noninvasive test that can be completed within a few minutes during a clinic visit. BIA does not require highly skilled personnel, and results are immediately available. This systematic review summarizes the literature pertaining to BIA assessment of sarcopenia in adults with cancer, with a focus on its use in diverse cancer populations.
肌肉质量的丧失，即肌肉减少症，是衰老的自然过程，无论年龄大小，与不良健康结果都有关联。由于癌症是一种老年病，因此人们对肌肉减少症及其在多种癌症人群中的潜在影响的兴趣显著增加。生物电阻抗分析（BIA）是一种被指南认可的肌少症检测方法。本系统评价评估了与 BIA 用于检测癌症成人中肌少症相关的文献。
在本系统评价中，通过 MEDLINE、Cochrane 中心数据库和 EMBASE 对随机对照试验和观察性研究进行了文献检索，检索时间截至 2019 年 7 月 15 日。该研究已在 Prospero（CRD42019130707）上注册。为了进行研究纳入，患者必须年满 18 岁，被诊断为实体或血液恶性肿瘤，并且必须使用 BIA 来检测肌少症。
通过我们的搜索策略，共确定了 5045 篇文章，其中 24 项研究被选入本综述（共纳入 3607 例患者）。在五项研究中，BIA 被认为与轴向计算机断层扫描（CT）扫描、小腿围或握力用于肌少症筛查具有可比性。在 14 项研究中，BIA 识别的肌少症与不良临床结局相关。
BIA 是一种在癌症患者接受治疗前检测肌少症的准确方法，并且是肿瘤学临床实践中 CT、双能 X 射线吸收法和磁共振成像的可行替代方法。
生物电阻抗分析（BIA）是一种在临床实践中识别肌少症患者的有吸引力的方法，因为它提供了一种经济实惠、非侵入性的测试，可以在就诊期间几分钟内完成。BIA 不需要高度熟练的人员，并且结果可以立即获得。本系统评价总结了与癌症成人 BIA 评估肌少症相关的文献，重点关注其在不同癌症人群中的应用。
